⌘K
Loading ticker…
Apogee Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Apogee Therapeutics, Inc. Common Stock (APGE) has a 3-month relative strength percentile of 93 and a leadership percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 86. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.7%, relative volume 0.98×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 93, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
APGE is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 48.5% / 84.7%.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
APGE is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.01% weight, $155M notional. Top 3 carry $339M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.01% | $155M |
| XBIState Street SPDR S&P Biotech ETF | 1.28% | $95M |
| IWMiShares Russell 2000 ETF | 0.12% | $89M |
| VXFVanguard Extended Market ETF | 0.06% | $50M |
| IWOiShares Russell 2000 Growth ETF | 0.25% | $30M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $5M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APGE Jan avg: -0.67% median: -8.70% win: 33% σ: 17.95% n: 3 2023-07-17 → 2026-05-29 | APGE Feb avg: -4.40% median: 3.94% win: 67% σ: 17.03% n: 3 2023-07-17 → 2026-05-29 | APGE Mar avg: 43.30% median: 20.24% win: 100% σ: 41.17% n: 3 2023-07-17 → 2026-05-29 | APGE Apr avg: -6.92% median: -1.52% win: 33% σ: 15.41% n: 3 2023-07-17 → 2026-05-29 | APGE May avg: -5.61% median: -6.65% win: 0% σ: 4.28% n: 3 2023-07-17 → 2026-05-29 | APGE Jun avg: 2.38% median: 2.38% win: 50% σ: 22.85% n: 2 2023-07-17 → 2026-05-29 (current) | APGE Jul avg: 4.22% median: 0.80% win: 67% σ: 18.08% n: 3 2023-07-17 → 2026-05-29 | APGE Aug avg: 2.44% median: 5.07% win: 67% σ: 6.48% n: 3 2023-07-17 → 2026-05-29 | APGE Sep avg: 5.63% median: 9.24% win: 67% σ: 11.41% n: 3 2023-07-17 → 2026-05-29 | APGE Oct avg: 3.90% median: -11.41% win: 33% σ: 33.61% n: 3 2023-07-17 → 2026-05-29 | APGE Nov avg: 9.17% median: 13.56% win: 67% σ: 20.56% n: 3 2023-07-17 → 2026-05-29 | APGE Dec avg: 16.14% median: 4.88% win: 100% σ: 23.55% n: 3 2023-07-17 → 2026-05-29 |